- Etamsylate
-
- $0.00 / 25Kg/Drum
-
2025-05-14
- CAS:2624-44-4
- Min. Order: 25KG
- Purity: 99.0%~101.0%; BP2010
- Supply Ability: 50tons/month
- Etamsylate
-
- $10.00 / 1KG
-
2025-04-23
- CAS:2624-44-4
- Min. Order: 1KG
- Purity: 99%
- Supply Ability: 10 mt
- Etamsylate
-
- $0.00 / 1kg
-
2025-04-15
- CAS:2624-44-4
- Min. Order: 1kg
- Purity: 99.0%
- Supply Ability: 1tons
|
| | Etamsylate Basic information |
| | Etamsylate Chemical Properties |
| Melting point | 125° | | density | 1.3441 (rough estimate) | | refractive index | 1.5060 (estimate) | | storage temp. | Keep in dark place,Inert atmosphere,Room temperature | | solubility | Very soluble in water, freely soluble in methanol, soluble in anhydrous ethanol, practically insoluble in methylene chloride. | | form | Solid | | color | White to Pale Red | | Merck | 14,3722 | | Stability: | Hygroscopic | | InChI | InChI=1S/C6H6O5S.C4H11N/c7-4-1-2-5(8)6(3-4)12(9,10)11;1-3-5-4-2/h1-3,7-8H,(H,9,10,11);5H,3-4H2,1-2H3 | | InChIKey | HBGOLJKPSFNJSD-UHFFFAOYSA-N | | SMILES | C1(S(=O)(=O)O)=CC(=CC=C1O)O.N(CC)CC | | CAS DataBase Reference | 2624-44-4(CAS DataBase Reference) | | EPA Substance Registry System | Ethamsylate (2624-44-4) |
| RTECS | DB6145000 | | HS Code | 2921.19.6190 | | HazardClass | IRRITANT | | Toxicity | LD50 i.v. in mice, rats: 800, 1350 mg/kg (Esteve) |
| | Etamsylate Usage And Synthesis |
| Chemical Properties | White Solid | | Uses | Haemostatic / Anti Coagulant | | Uses | Hemostatic;prostaglandin synthesis inhibitor | | Definition | ChEBI: Etamsylate is a sulfonic acid derivative and an organosulfur compound. | | Biological Activity | Etamsylate is a haemostatic agent th at is used for the management of blood loss. Apparently etamsylate increases capillary wall resistance and platelet adhesives by inhibition of the biosynthesis of prostaglandins causing platelet disaggregation in a presence of vascular wound. Recent studies suggest th at etamsylate antagonizes anti-coagulant activity of heparin. | | Mechanism of action | Etamsylate is an antihaemorrhagic and vasoprotective agent. It increases platelet adhesiveness and capillary vascular wall resistance, thereby reducing capillary exudation and blood loss.
| | Clinical Use | Short-term treatment of blood loss in menorrhagiaProphylaxis of surgical bleeding (unlicensed) | | Side effects |
Significant: Hypotension (parenteral). Rarely, severe hypersensitivity reaction, including anaphylaxis.
Blood and lymphatic system disorders: Parenteral: Rarely, neutropenia, agranulocytosis, thrombocytopenia.
Gastrointestinal disorders: Nausea, vomiting, diarrhoea, abdominal pain or discomfort.
General disorders and administration site conditions: Asthenia (parenteral). Rarely, fever.
Musculoskeletal and connective tissue disorders: Rarely, arthralgia.
Nervous system disorders: Headache.
Skin and subcutaneous tissue disorders: Rash.
Vascular disorders: Rarely, thromboembolism (parenteral).
| | Metabolism | Etamsylate is excreted unchanged, mainly in the urine. |
| | Etamsylate Preparation Products And Raw materials |
|